Clinical Trials Directory

Trials / Completed

CompletedNCT00941057

Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium

Open-label, Randomized, Cross-over Study to Investigate the Bioequivalence of Estradiol Valerate (EV), Dienogest (DNG) and Levomefolate Calcium After Single Oral Administration of a Tablet Formulation Containing 2 mg Estradiol Valerate and 3 mg Dienogest Without and With 0.451 mg Levomefolate Calcium and a Tablet Formulation Containing 0.451 mg Levomefolate Calcium in 42 Healthy Postmenopausal Women

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
43 (actual)
Sponsor
Bayer · Industry
Sex
Female
Age
45 Years – 75 Years
Healthy volunteers
Accepted

Summary

Investigation of the bioequivalence (BE) of Estradiol Valerate (EV) and Dienogest (DNG) after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 2 mg Estradiol Valerate,3 mg Dienogest.Investigation of the bioequivalence of levomefolate calcium after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 0.451 mg levomefolate calcium

Conditions

Interventions

TypeNameDescription
DRUGBAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calciumOral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
DRUGBAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
DRUGBAY 86-7660,levomefolate calciumOral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days

Timeline

Start date
2009-09-01
Primary completion
2009-12-01
Completion
2010-01-01
First posted
2009-07-17
Last updated
2016-08-01

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00941057. Inclusion in this directory is not an endorsement.